Literature DB >> 17933842

Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease.

Nigel D Toussaint1, Kenneth K Lau, Boyd J Strauss, Kevan R Polkinghorne, Peter G Kerr.   

Abstract

BACKGROUND: Vascular calcification (VC) and arterial stiffness are major contributors to cardiovascular (CV) disease in chronic kidney disease (CKD). Both are independent predictors of CV mortality and are inversely correlated with bone mineral density (BMD). Few studies have addressed the extent of VC in the pre-dialysis CKD population, with associated measurements of BMD and arterial compliance.
METHODS: We report cross-sectional data on 48 patients with CKD (GFR 17-55 ml/min) assessing the prevalence of VC and its associations. All patients had computed tomography (CT) scans through abdominal aorta and superficial femoral arteries (SFAs) to determine VC, pulse wave velocity (PWV) using SphygmoCor device (AtCor PWV Inc., Westmead, Australia) measuring arterial stiffness, and dual-energy X-ray absorptiometry (DEXA) scans to determine BMD, as well as serum markers of renal function and mineral metabolism.
RESULTS: Patients, 71% male, 54% diabetic, had a median age 64.5 years. Mean estimated GFR was 35.1 +/- 10 ml/min. Mean PWV was 10.0 +/- 4.5 m/s and mean aortic VC score was 421.5 +/- 244 Hounsfield units, with 90% of subjects having some aortic VC present. In univariate linear regression analysis, aortic VC correlated positively with age (r 0.50, P < 0.001), triglycerides (r 0.47, P = 0.002) and PWV (r 0.33, P = 0.03). There was also greater VC with declining renal function (r -0.28, P = 0.05). There was no significant association between VC and serum markers of mineral metabolism, however phosphate and Ca x P correlated positively with PWV (r 0.35, P = 0.02, r 0.36, P = 0.02, respectively). There was also a positive association between PWV and triglycerides (P = 0.008), and a trend towards greater PWV with increasing age (P = 0.09). In multivariate regression analysis only increasing age and triglyceride levels were significantly associated with aortic VC and PWV. Mean spine and femoral T-scores on DEXA were 0.48 and -1.31 respectively, with 13% of subjects having femoral T-score <-2.5 (osteoporotic range). SFA VC inversely correlated with femoral T-scores (r -0.43, P = 0.004); however, there was a positive (likely false) association between spine T-scores and aortic VC (r 0.37, P = 0.01), related to the limitation of vertebral DEXA in CKD.
CONCLUSION: There is a high prevalence of VC in pre-dialysis CKD patients, worse with increasing age, triglycerides and reducing renal function. Correlation exists between VC and PWV and determination of one or both may be useful for CKD patient CV risk assessment. Femoral BMD is inversely associated with SFA VC, but measurement of vertebral BMD by DEXA is unreliable in CKD patients with aortic VC.

Entities:  

Mesh:

Year:  2007        PMID: 17933842     DOI: 10.1093/ndt/gfm660

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  77 in total

Review 1.  Strategies for Achieving Healthy Vascular Aging.

Authors:  Kristen L Nowak; Matthew J Rossman; Michel Chonchol; Douglas R Seals
Journal:  Hypertension       Date:  2018-01-08       Impact factor: 10.190

2.  Aortic pulse wave velocity is greater in peritoneal dialysis patients with lower dual energy X-ray absorptiometry (DXA) femoral neck bone mineral density.

Authors:  Kamonwan Tangvoraphonkchai; Andrew Davenport
Journal:  J Nephrol       Date:  2018-12-10       Impact factor: 3.902

3.  Bone mineral density and parathyroid function in patients on maintenance hemodialysis.

Authors:  Cs Ambrus; Cs Almasi; K Berta; Gy Deak; A Marton; M Zs Molnar; Zs Nemeth; Cs Horvath; P Lakatos; M Szathmari; I Mucsi
Journal:  Int Urol Nephrol       Date:  2010-01-21       Impact factor: 2.370

4.  Serum calcification propensity predicts all-cause mortality in predialysis CKD.

Authors:  Edward R Smith; Martin L Ford; Laurie A Tomlinson; Emma Bodenham; Lawrence P McMahon; Stefan Farese; Chakravarthi Rajkumar; Stephen G Holt; Andreas Pasch
Journal:  J Am Soc Nephrol       Date:  2013-10-31       Impact factor: 10.121

5.  Arterial compliance across the spectrum of ankle-brachial index: the Multiethnic Study of Atherosclerosis.

Authors:  Scott M Lilly; David R Jacobs; Richard Kronmal; David A Bluemke; Michael Criqui; Joao Lima; Matthew Allison; Daniel Duprez; Patrick Segers; Julio A Chirinos
Journal:  Atherosclerosis       Date:  2014-02-12       Impact factor: 5.162

6.  Bone Mineral Density as a Predictor of Atherosclerosis and Arterial Wall Stiffness in Obese African-American Women.

Authors:  Samy I McFarlane; Ghazanfar Qureshi; Gagandeep Singh; Kinda Venner-Jones; Louis Salciccioli; Jason Lazar
Journal:  Cardiorenal Med       Date:  2012-11-24       Impact factor: 2.041

7.  Increased risk of cardiovascular events in end-stage renal disease patients with osteoporosis: a nationwide population-based cohort study.

Authors:  T-M Yu; C-L Lin; K-H Shu; Y-L Liu; C-H Chen; S-T Huang; C-H Kao
Journal:  Osteoporos Int       Date:  2014-12-10       Impact factor: 4.507

8.  Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients?

Authors:  S Pelletier; C B Confavreux; J Haesebaert; F Guebre-Egziabher; J Bacchetta; M-C Carlier; L Chardon; M Laville; R Chapurlat; G M London; M-H Lafage-Proust; D Fouque
Journal:  Osteoporos Int       Date:  2015-04-25       Impact factor: 4.507

9.  Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease.

Authors:  P Manghat; W D Fraser; A S Wierzbicki; I Fogelman; D J Goldsmith; G Hampson
Journal:  Osteoporos Int       Date:  2009-12-09       Impact factor: 4.507

10.  Assessment of abdominal aortic calcification at different stages of chronic kidney disease.

Authors:  Zeynep Biyik; Nedim Yilmaz Selcuk; Halil Zeki Tonbul; Melih Anil; Mehmet Uyar
Journal:  Int Urol Nephrol       Date:  2016-09-12       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.